HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?

被引:28
|
作者
Husereau, Don [1 ]
Marshall, Deborah A. [2 ]
Levy, Adrian R. [3 ]
Peacock, Stuart [4 ]
Hoch, Jeffrey S. [5 ]
机构
[1] Univ Ottawa, Univ Hlth Sci Med Informat & Technol, Inst Hlth Econ, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada
[2] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 4Z6, Canada
[3] Dalhousie Univ, Fac Med, Dept Community Hlth & Epidemiol, Halifax, NS B3H 1V7, Canada
[4] Univ British Columbia, Canadian Ctr Applied Res Canc Control, British Columbia Canc Res Ctr, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada
[5] Canadian Ctr Appl Res Canc Control, Pharmacoecon Res Unit, Canc Care Ontario, Toronto, ON M5G 2L7, Canada
关键词
Costs and cost analysis; Biomedical research/methods; Biomedical research/standards; Decision support techniques; Delivery of health care; Diagnostic techniques and procedures; Health policy; Humans; Individualized medicine/methods; Technology assessment; Biomedical; COST-EFFECTIVENESS ANALYSIS; BREAST-CANCER; HETEROGENEITY; FRAMEWORK; TESTS; WOMEN;
D O I
10.1017/S0266462314000142
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Many jurisdictions delivering health care, including Canada, have developed guidance for conducting economic evaluation, often in the service of larger health technology assessment (HTA) and reimbursement processes. Like any health intervention, personalized medical (PM) interventions have costs and consequences that must be considered by reimbursement authorities with limited resources. However, current approaches to economic evaluation to support decision making have been largely developed from population-based approaches to therapy-that is, evaluating the costs and consequences of single interventions across single populations. This raises the issue as to whether these methods, as they are or more refined, are adequate to address more targeted approaches to therapy, or whether a new paradigm for assessing value in PM is required. Objectives: We describe specific issues relevant to the economic evaluation of diagnostics-based PM and assess whether current guidance for economic evaluation is sufficient to support decision making for PM interventions. Methods: Issues were identified through literature review and informal interviews with national and international experts (n = 10) in these analyses. This article elaborates on findings and discussion at a workshop held in Ottawa, Canada, in January 2012. Results: Specific issues related to better guiding economic evaluation of personalized medicine interventions include: how study questions are developed, populations are characterized, comparators are defined, effectiveness is evaluated, outcomes are valued and how resources are measured. Diagnostics-based PM also highlights the need for analyses outside of economic evaluation to support decision making. Conclusions: The consensus of this group of experts is that the economic evaluation of diagnostics-based PM may not require a new paradigm. However, greater complexity means that existing approaches and tools may require improvement to undertake these more analyses.
引用
收藏
页码:179 / 187
页数:9
相关论文
共 50 条
  • [41] Enhancing Immunization Clinical Decision Support to Support Personalized Guidance and Shared Decision Making Recommendations
    Michel, Jeremy
    Vo, Nghi
    Lawton, Lawrence
    Grundmeier, Robert
    Thayer, Jeritt
    PEDIATRICS, 2022, 149 (01)
  • [42] Economic evaluation in the health care decision making process: The case of England
    Castillo-Laborde, Carla
    REVISTA MEDICA DE CHILE, 2010, 138 : 103 - 107
  • [43] ECONOMIC-EVALUATION AND DECISION-MAKING IN ENVIRONMENTAL-HEALTH
    ZUNIGA, CG
    PENA, PH
    GUERRERO, CO
    FERNANDEZ, RZ
    SANTOSBURGOA, C
    REVISTA DE SAUDE PUBLICA, 1994, 28 (02): : 153 - 166
  • [44] Risk Assessment and Personalized Decision Support: The University of California Athena Breast Health Network
    Ozanne, E. M.
    Crawford, B.
    Petruse, A.
    Madlensky, L.
    Weiss, L.
    Hogarth, M.
    Wenger, N.
    Goodman, D.
    Park, H.
    Anton-Culver, H.
    Yasmeen, S.
    Howell, L.
    Ojeda, H.
    Parker, B. A.
    Kaplan, C.
    van't Veer, L.
    Esserman, L.
    Naeim, A.
    CANCER RESEARCH, 2012, 72
  • [45] DISCOUNTING AND DECISION MAKING IN THE ECONOMIC EVALUATION OF HEALTH-CARE TECHNOLOGIES
    Claxton, Karl
    Paulden, Mike
    Gravelle, Hugh
    Brouwer, Werner
    Culyer, Anthony J.
    HEALTH ECONOMICS, 2011, 20 (01) : 2 - 15
  • [46] HIA, health impact assessment: a multidisciplinary procedure to support decision making in public health
    Bianchi, Fabrizio
    Lauriola, Paolo
    EPIDEMIOLOGIA & PREVENZIONE, 2011, 35 (02): : 73 - 76
  • [47] DEVELOPMENT AND TEST OF A DECISION SUPPORT TOOL FOR HOSPITAL HEALTH TECHNOLOGY ASSESSMENT
    Sampietro-Colom, Laura
    Morilla-Bachs, Irene
    Gutierrez-Moreno, Santiago
    Gallo, Pedro
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 460 - 465
  • [48] From health to wealth: The future of personalized medicine in the making
    Tarkkala, Heta
    Helen, Ilpo
    Snell, Karoliina
    FUTURES, 2019, 109 : 142 - 152
  • [49] HEALTH TECHNOLOGY ASSESSMENT OF COMPANION DIAGNOSTIC BIOMARKERS AS GATEKEEPERS FOR PERSONALIZED MEDICINE MARKET ACCESS
    Spinner, D. S.
    Ransom, J. F.
    Culp, J. L.
    Chawla, A. S.
    Doyle, J. J.
    Faulkner, E. C.
    VALUE IN HEALTH, 2013, 16 (07) : A376 - A376
  • [50] Correlating Health and Wellness Analytics for Personalized Decision Making
    Khan, Wajahat Ali
    Idris, Muhammad
    Ali, Taqdir
    Ali, Rahman
    Hussain, Shujaat
    Hussain, Maqbool
    Amin, Muhammad Bilal
    Khattak, Asad Masood
    Yuan Weiwei
    Afzal, Muhammad
    Lee, Sungyoung
    Kang, Byeong Ho
    2015 17TH INTERNATIONAL CONFERENCE ON E-HEALTH NETWORKING, APPLICATION & SERVICES (HEALTHCOM), 2015, : 256 - 261